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High-titer antibodies against a cellular thyroid hormone-binding protein (Mr 58 000, ~58) were developed by a special 
immunization method. To enhance immune responses, this method uses a boosting protocol in which repeated injections 
of small amounts of antigen are administered at 2-day intervals. Antibodies were detected 1 week after the last injection 
of antigen by ELISA, Western dot blotting and immunoprecipitation. The anti-p58 antibodies recognize ~58 which is 
bound to the thyroid hormone. With the availability of anti-p58 antibodies, it has become possible to study cellular local- 
ization and function. 
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1. INTRODUCTION 
Recent studies have indicated that the entry of 
the thyroid hormone 3,3 ’ ,$triiodo-L-thyronine 
(Ts) into cells is a receptor- or carrier-mediated 
process. This process has been extensively 
characterized in isolated hepatocytes [l-3] and 
cultured cells [4-61. The results indicate that a 
cellular protein is involved in T3 uptake. 
Recently, we have isolated a cellular T3-binding 
protein of M, 58000 (~58). This protein has now 
been purified to apparent homogeneity and retains 
its T3-binding activity [6]. In order to determine its 
intracellular location and role in thyroid hormone 
transport, and to clone its gene, specific antibodies 
against ~58 would be useful. However, attempts to 
develop antibodies using conventional immuniza- 
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tion protocols met with failures. The present work 
describes a special method which gives high-titer 
antibodies against ~58. Furthermore, the level of 
antibodies was found to be maintained for up to 5 
months. 
2. MATERIALS AND METHODS 
[3,3 ’ ,5-“‘1]Tp (2200 Ci/mmol) was from New England 
Nuclear, CHAPS from Sigma and goat anti-mouse im- 
munoglobulin from Cappel. The avidin/biotin/avidin- 
horseradish peroxidase system (ABC kit) was from Vector 
Laboratories. A43 1 cells were propagated in Dulbecco-Vogt’s 
medium containing 10% fetal calf serum as in [7]. 
2.1. Immunization 
Native p58 was purified as in [6]. 5 gg purified p58 was mixed 
with an equal volume of complete adjuvant and half was in- 
jected into mice intraperitoneally and half subcutaneously. 3
weeks later, 2 ,ug purified p58 with incomplete adjuvant was in- 
troduced similarly. 2 days later, 2 pg p58 in 200-500 /tl PBS 
was injected intraperitoneally. The injection was repeated for 
an additional four times at intervals of 2 days. Sera were screen- 
ed 1 week after the last boost. 
SDS-denatured and hemocyanin-conjugated p58 were also 
used as immunogens. SDS-denatured ~58 was obtained by elu- 
tion of p58 from SDS-polyacrylamide gels as described [7]. 
Conjugation of ~58 to hemocyanin was carried out using 
2-iminothiolane as a cross-linking reagent according to [8]. 
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2.2. ELBA assay 
Assays were carried out at 22’C. Purified ~58 (0.1 pg/40 pl 
of 0.5 mM CHAPS in 80 mM phosphate buffer) was added to 
each well in 96-well microtiter plates (Dynetech). Blocking, 
washing and reaction with substrate were performed as in [9]. 
2.3. Western dot blotting 
~58 (0.05/1g) was spotted onto nitrocellulose paper. After 
drying, ~58 was reacted with immune serum in various dilu- 
tions. The ABC kit was used to identify positive serum as 
described in [9]. 
2.4. Metabolic labeling and immunoprecipitation 
A431 cells were labeled with [“Slmethionine for 20 h. 
CHAPS extractions of cells and immunoprecipitation were car- 
ried out as in [lo]. 
2.5. Immunoprecipitation of ~ZSI/T~-bound ~58 
Binding of ~58 with [r2sI]Ts was carried out as described [6]. 
The [“‘I]Ts-bound ~58 was immunoprecipitated by incubation 
with 10 ~1 anti-p58 antiserum in 0.5 ml binding buffer at 4OC 
for 30 min. Goat anti-mouse immunoglobulin (1.79 mg in 
100 ~1 binding buffer) was added. After incubation for 30 min 
at 4”C, the immune complex was pelleted by centrifugation at 
11000 x g for 15 min. Radioactivity was determined by a 
y-counter. 
3. RESULTS 
3.1. Immunization 
Table 1 lists the immunogens which have been 
used in attempts to elicit antibodies against human 
~58. Native SDS-treated and hemocyanin- 
conjugated ~58 were used as immunogens. The 
Table 1 
Immunization with ~58 
Immunogen Primary First boostb Second boostb 
injectiona +g) (ug) &g) 
SDS-treated ~58 5 5 5 
SDS-treated ~58 
conjugated to 
hemocyanin 5-q 5-10 5-10 
Native ~58 
conjugated to 
hemocyanin 5 5 5 
Native ~58 5 2 2’ 
a Complete adjuvant 
b Antigen was mixed with incomplete adjuvant and injected 3 
weeks after primary injection 
a*b Half of the antigen was administered intraperitoneally and 
half subcutaneously 
c Boosting was repeated 5 times at an interval of 2 days 
without adjuvant. Antigen was injected intraperitoneally 
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Fig.1. Titration of anti-p58 antiserum by ELISA assay. 
(o--o) Immune serum, (O---O) preimmune serum. 
amounts of modified and unmodified immunogen 
used were similar. However, except for one in 
which a special protocol was used in the second 
boost, all failed to elicit antibody production. 
When native ~58 was injected repeatedly at 2-day 
intervals into five mice, anti-p58 antibodies were 
detectable in three mice 1 week after the final injec- 
tion. The two remaining mice also developed anti- 
~58 antibodies 2 weeks later. The same protocol 
was repeated in another experiment; high-titer an- 
tibodies were detected in all five mice 1 week after 
the last administration of antigen. The antibody 
levels were monitored periodically and found to be 
maintained at high levels for up to 5 months. 
3.2. Detection of anti-p58 antibodies 
Screening of anti-p58 antibodies in mice was car- 
ried out using the following methods. (i) ELISA 
assay. Fig. 1 shows the concentration dependence 
of the immunoreactivity of mouse no.3 antiserum. 
At 1: 5000 dilution of serum, the antibody is still 
detectable, whereas the preimmune serum yielded 
only the background reading. The sera from the 
other four mice have similar titers. (ii) Western dot 
blotting. Fig.2 shows the concentration 
dependence of the immunoreactivity of the serum 
from mouse no.3 where 50 ng purified ~58 is spot- 
ted onto nitrocellulose. The reactivity is concentra- 
tion dependent and detectable at 1: 500 dilution. 
(iii) Immunoprecipitation of [“Slmethionine- 
labeled cellular extracts. Fig.3 shows the 
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Fig.2. Titration of anti-p58 antiserum by Western dot blotting. Purified ~58 (0.05 ,ug) was spotted onto nitrocellulose paper and reacted 
with increasing dilutions of sera. (l-2) Preimmune serum, (3-10) immune serum; serum dilution (l-4) 1: 10, (5,6) 1: 100, (7,8) 1:500, 
(9,lO) 1: 1000. 
autoradiogram of immunoprecipitable protein 
bands from mouse no.3 antiserum at three dilu- 
tions. Compared to lane 1 in which preimmune 
serum was used, lanes 2-4 showed three specific 
bands of 91, 58 and 38 kDa, respectively. The 58 
and 38 kDa bands are the most intense. The 
38 kDa protein could be the degradation product 
Fig.3. Autoradiogram of the immunoprecipitates from 
[35S]methionine-labeled c llular extracts by anti-p58 antiserum. 
A431 cells (5 x lo6 cells/100 mm dish) were labeled with 
[35S]methionine (1mCi) for 20 h at 37°C. Cells were extracted 
using CHAPS and immunoprecipitated with a 1: 50 dilution of 
preimmune serum (lane 1) and 1: 50 (lane 2), 1: 500 (lane 3) and 
1: 5000 (lane 4) dilutions of immune serum. 
of ~58. Since this is a polyclonal antibody, it is not 
unexpected to find minor contaminating proteins, 
such as 91 kDa protein, being co-immuno- 
precipitated. Comparing lanes 2 and 3, less p58 is 
immunoprecipitated at 1:50 dilution than at 
1: 500, indicating that the immunoglobulins exceed 
the binding capacity of Staphylococcus aureus. On 
further dilution of serum, immunoprecipitation of 
the p58 band became concentration-dependent. 
(iv) Immunoprecipitation of [“‘I]Ts-bound ~58. 
To determine whether the antigenic sites are 
directed against the binding of T3 to ~58, ~58 pre- 
bound to [“‘I]Ts was immunoprecipitated using 
goat anti-mouse IgG as second antibody. As 
shown in table 2, nearly 2-fold more [1251]T3 bound 
to ~58 was immunoprecipitated as compared to 
Table 2 
Immunoprecipitation of [‘251]Ts-bound ~58 
Serum [iZ51]Ts-bound ~58 antibody 
complexa (dpm x 10e3) 
- Dissociation with 
unlabeled Tsb 
Immune 8.9 3.3 
Preimmune 4.5 3.2 
a Purified ~58 (1.9 +g) was incubated with 2 nM [rZ51]T3 in
500~1 binding buffer at 4°C for 30 min. The [‘251]Ts-bound 
~58 was separated from free [rz51]Ts as described in section 2. 
[rZ51]Ts-bound ~58 was divided into two equal aliquots and 
incubated with 10,ul immune or preimmune serum for 
30 min. Goat anti-mouse immunoglobulin (1.8 mg) was used 
to precipitate [‘251]Ts-bound ~58 immune complex as 
described in the text 
b The immune complex obtained by centrifugation was 
resuspended in binding buffer (500~1) in the presence or 
absence of 20/M Ts for 30 min. The immune complex was 
pelleted by centrifugation at 11000 x g for 10 min and 
counted 
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preimmune serum. When the immune complex was cedure is highly reproducible. When the same 
subsequently treated with excess unlabeled T3 protocol was repeated in the second set of five 
(20 PM), nearly all specifically bound [‘?]T3 was mice, virtually the same results were obtained. This 
displaced by unlabeled T3. These results indicate immunization method may be useful in the 
that the antigenic sites of the antibodies are unlike- development of antibodies against antigens which 
ly to be against T3-binding sites. have been shown to be weak or nonimmunogenic. 
4. DISCUSSION 
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